The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

The radio queen went for a dip at Sydney 's Clovelly beach where she did laps in the tide pool. The 49-year-old showed off ...

The former Big Brother contestant, 46, stripped completely as she flaunted her jaw-dropping figure for the X-rated Closer ...

Another option, minus the injection Novo Nordisk also manufactures Rybelsus, which is an oral semaglutide tablet approved for the treatment of type 2 diabetes. Novo Nordisk is seeking FDA approval ...

The weight loss drug semaglutide was a "miracle" for Staci Rice. Her cravings and "food noise" disappeared, and it help her lose 64 pounds in around eight months. But, even in its cheaper forms ...

Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market.

Millions of Part D patients who rely on price-controlled drugs will see their out-of-pocket medication costs increase.

Courtesy Staci Rice, Classified as a GLP-1, appetite-suppressing medications, semaglutide is the active ingredient in anti-obesity jabs like Wegovy, and in the anti-diabetes drug Ozempic.

The type 2 diabetes medication, generically known as semaglutide, has received unprecedented attention in the press and the medical community for its ability to trigger profound weight loss.

Viking Therapeutics struggles with FDA approval and scaling up. Find out why VKTX stock’s path remains uncertain, despite its ...